Organigram Down On COVID-19 Impact, Buying Opportunity In Sight
Cannabis investors that didn’t get the message when Aphria (NASDAQ: APHA) reported should pay attention to Organigram (NASDAQ: OGI). The company just reported its worst results since the 2018 cannabis market implosion and has shares down by 10%.
Depositphotos.com contributor/Depositphotos.com via MarketBeat
This story originally appeared on MarketBeat
Lockdowns Cut Into Organigram Revenue
get the message NASDAQ: APHA NASDAQ: OGIOrganigram Revenue Shrinks But The Story Is Bigger Than COVID
revenue shrank dried-flower- Q2 2021 net revenue was also lower due to missed sales opportunities, as certain employees tested positive for COVID-19 which resulted in a significant number of facility staff having to isolate.
The Technical Outlook: Organigram Down But Not Out
Featured Article: Trading Penny Stocks
Lockdowns Cut Into Organigram Revenue
get the message NASDAQ: APHA NASDAQ: OGIOrganigram Revenue Shrinks But The Story Is Bigger Than COVID
revenue shrank dried-flower- Q2 2021 net revenue was also lower due to missed sales opportunities, as certain employees tested positive for COVID-19 which resulted in a significant number of facility staff having to isolate.
The Technical Outlook: Organigram Down But Not Out
Featured Article: Trading Penny Stocks
